Journal Article

DKFZ-2017-05939

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer.

Werner, S. (First author)DKFZ* ; Chen, H.DKFZ* ; Butt, J. A.DKFZ* ; Michel, A.DKFZ* ; Knebel, P. ; Holleczek, B. ; Zörnig, I.DKFZ* ; Eichmüller, S.DKFZ* ; Jäger, D.DKFZ* ; Pawlita, M.DKFZ* ; Waterboer, T.DKFZ* ; Brenner, H. (Last author)DKFZ*

2016
Nature Publishing Group London

This record in other databases:  

Please use a persistent id in citations: doi:10.1038/srep25467

Abstract: Autoantibodies against tumor-associated antigens (TAAs) have been suggested as biomarkers for early detection of gastric cancer. However, studies that systematically assess the diagnostic performance of a large number of autoantibodies are rare. Here, we used bead-based multiplex serology to simultaneously measure autoantibody responses against 64 candidate TAAs in serum samples from 329 gastric cancer patients, 321 healthy controls and 124 participants with other diseases of the upper digestive tract. At 98% specificity, sensitivities for the 64 tested autoantibodies ranged from 0-12% in the training set and a combination of autoantibodies against five TAAs (MAGEA4 + CTAG1 + TP53 + ERBB2_C + SDCCAG8) was able to detect 32% of the gastric cancer patients at a specificity of 87% in the validation set. Sensitivities for early and late stage gastric cancers were similar, while chronic atrophic gastritis, a precursor lesion of gastric cancer, was not detectable. However, the 5-marker combination also detected 26% of the esophageal cancer patients. In conclusion, the tested autoantibodies and combinations alone did not reach sufficient sensitivity for gastric cancer screening. Nevertheless, some autoantibodies, such as anti-MAGEA4, anti-CTAG1 or anti-TP53 and their combinations could possibly contribute to the development of cancer early detection tests (not necessarily restricted to gastric cancer) when being combined with other markers.

---

Contributing Institute(s):

1. Klinische Epidemiologie und Alternsforschung (C070)
2. Präventive Onkologie (G110)
3. DKTK Heidelberg (L101)
4. Angewandte Tumor-Immunität (D120)
5. Geschäftsstelle (G010)
6. Molekulare Diagnostik Oncogener Infektionen (F020)
7. GMP Einheit Zelluläre Therapie (G182)

Research Program(s):

1. 313 - Cancer risk factors and prevention (POF3-313) (POF3-313)

Appears in the scientific report 2016

---

Database coverage:
; ; ; BIOSIS Previews ; Current Contents - Physical, Chemical and Earth Sciences ; DOAJ Seal ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection ; Zoological Record

---